Takeda told to put Japanese house in order over 'misleading advertisements'
This article was originally published in SRA
Executive Summary
Takeda has received a business improvement order from the Japanese government over "inappropriate" promotional materials for the company's blockbuster antihypertensive, Blopress (candesartan).